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The global burden of end-stage renal disease is grow-
ing [1]. During the last decade, the dialysis population
has been growing at an average of 7% per year. There
are now approximately 1.1 million people worldwide on
renal replacement therapy, and, according to reliable es-
timates, the number of maintenance dialysis patients will
double in 10 years. The total cumulative cost for re-
nal replacement therapy in the next decade will exceed
$1 trillion [2], a really shocking figure from any point of
view.
Renal replacement therapy is widely available for any-
one in need in high-income countries, while in middle-
income countries treatment is restricted to a selected
population of patients. No treatment at all is available
in low-income countries, where people with chronic kid-
ney disease are dying of uremia [3].
The impossibility to have access to a life-saving treat-
ment such as dialysis in many parts of the world under-
lines dramatically the existing inequalities that do not
have any prospect of solution. In fact, during the next
decade, the possibility that low-income countries could
afford dialysis programs is unlikely, while even high-
income countries have to face the prospect of some form
of rationed care.
How could the global burden of chronic kidney dis-
ease be diminished in the future? At the present, there
are no definitive cures for most acquired kidney diseases,
and there is not reasonable expectation that gene therapy
will be available soon enough to treat genetic forms of
kidney diseases, such as polycystic kidney disease. Renal
transplantation is limited by organ shortage [4], a world-
wide problem that is not likely to be soon resolved by
xenotransplantation. The best we can do at the present
time is to concentrate our efforts in the prevention of
progression of renal diseases.
During the last 20 years we have learned a great deal
concerning the mechanisms involved in the progression
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of kidney disease, and we have devised strategies, based
on a combination of drug interventions and lifestyle
changes, to prevent it. The challenge for the future is
to improve our knowledge on these mechanisms and
discover other tools for protecting renal function from
progressive deterioration. Also, a major task will be to
reach all those who could benefit of the currently avail-
able treatment strategies, in the rich as well in the poor
countries.
MECHANISMS OF PROGRESSION
Glomerular hypertension and hyperfiltration
In 1982, the somewhat somnolent world of nephrol-
ogy was abruptly awakened by Brenner, Meyers, and
Hostetter [5] who exposed their hypothesis on the mech-
anisms of progression of chronic kidney disease in a sem-
inal paper. Central to their hypothesis was the concept,
later confirmed by an abundance of experimental data
from their Boston laboratory and from many others in
the world, that progressive deterioration of renal func-
tion was the result of compensatory glomerular hemody-
namic changes in response to nephron loss. In a widely
used experimental model of renal mass reduction, the
remaining nephrons undergo hypertrophy, reduced arte-
riolar resistance, and increased glomerular blood flow [6].
Since afferent arteriolar tone decreases more than the ef-
ferent one, intraglomerular pressure and the amount of
filtrate formed by single nephron rise.
The role of angiotensin II
The role of angiotensin II in progression of renal
disease has been object of extensive investigation (for a
review, see [7]). In vivo, angiotensin II enhances the
vascular tone of both afferent and efferent glomerular
arterioles and modulates intraglomerular capillary pres-
sure and glomerular filtration rate (GFR). Angiotensin
II exerts its vasoconstrictor effect predominantly on the
postglomerular arterioles, thereby increasing the
glomerular hydraulic pressure and the filtration frac-
tion. High glomerular capillary pressure increases the
radius of the pores in the glomerular membrane, thus
impairing the size-selective function of the membrane
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to the macromolecules [8]. Besides these glomerular
hemodynamic effects of angiotensin II, other studies
have revealed several nonhemodynamic effects of
angiotensin II that may also be important. In isolated
perfused kidneys, infusion of angiotensin II results in a
loss of glomerular size permselectivity and proteinuria,
an effect that has been attributed to both hemody-
namic activity of angiotensin II and its direct effect
on glomerular permselectivity [9]. Podocytes have a
complex cytoskeleton with contractile properties, and
there are angiotensin II receptors on their surface
[10]. These findings have suggested that angiotensin II
may alter permselective properties of the glomerular
barrier by mediating contraction of the foot processes
ultimately changing slit diaphragm architecture and
allowing proteins to escape more easily into the urinary
space [11]. Evidence that angiotensin II depolarizes
podocytes by opening a chloride conductance related
to cytoskeleton via an angiotensin II type 1 receptor
is in line with such a possibility [12]. Angiotensin II
concentration in the Bowman’s space is up to 1000-fold
higher than in the vasculature space, suggesting that
angiotensin II is produced by local renin-angiotensin
system.
Angiotensin II also modulates renal cell growth, which,
in turn, may contribute to tubulointerstitial injury [13].
Increased expression of c-fos and Egr-1, the immediate
early genes whose activation precedes cell proliferation,
has been shown in proximal tubular cells exposed to an-
giotensin II [14].
The peptide, acting through angiotensin II type 1 re-
ceptors, also induces hypertrophy in tubular cells by up-
regulating the gene for transforming growth factor b1
(TGF-b1), which, in turn, leads to increased synthesis
of collagen type IV [15]. Remodeling of the interstitial
architecture may also occur as a result of transformation
of tubular cells, an additional event promoted by the en-
hanced synthesis of TGF-b1 stimulated by angiotensin
[16].
Angiotensin II also stimulates the production of plas-
minogen activator inhibitor-1 (PAI-1) and may therefore
further increase the accumulation of the extracellular ma-
trix through inhibition of its breakdown by matrix metal-
loproteinases, which require the conversion to an active
form by plasmin [17]. By stimulating macrophage acti-
vation and phagocytosis, angiotensin II may enhance the
inflammatory component associated with chronic renal
injury [18]. Angiotensin II up-regulates genes and stim-
ulate secretion of peptides with chemotactic and vasoac-
tive properties [19].
In experimental animals, repeated infusions of an-
giotensin II cause interstitial fibrosis and lead to the
deposit of type IV collagen, a process that suggests the
morphogenic effect of angiotensin II on tubulointerstitial
structure [20].
Proteinuria
Proteinuria is not merely a consequence of glomeru-
lar hyperfiltration, a marker of altered glomerular
barrier integrity. Soon after the formulation of the
Brenner’s hypothesis, it was proposed that abnormal pro-
tein trafficking through the glomerular capillary might
also contribute to progression of renal disease.
In rats with age-related proteinuria [21], or with
adriamycin-induced nephrosis [22], protein reabsorption
droplets accumulated in the proximal tubular cells. Also,
focal breaks of tubular basement membranes, and ex-
travasation of the tubular content in the renal interstitium
were demonstrated in rat renal biopsies.
Both in vitro and in vivo, protein overload causes
increased production of inflammatory mediators such
as endothelin-1, monocyte chemoattractant protein-1
(MCP-1), regulated upon activation, normal T cell ex-
pressed and secreted (RANTES), a chemotactic cytokine
for monocytes and memory T cells and osteopontin
[23]. The molecular mechanisms that lead to chemokine
overexpression are mediated by nuclear factor-kappaB
(NF-kB), a transcription factor that promotes nuclear
translocation of the DNA [24, 25]. There is in vitro ev-
idence that albumin and IgG caused a dose-dependent
increase in NF-kB activation in proximal tubular cells, an
event that is followed by up-regulation of RANTES and
MCP-1 [26, 27].
In specimen of renal biopsies of patients with severe
proteinuria, NF-kB activation has been shown in tubular
cells, concomitant to up-regulation of proinflammatory
chemokines [28].
Complement components also may play a major role
in proteinuria-induced interstitial damage. Complement
proteins are filtered through the glomerulus, and de-
posits of C3 and C5b-9 are found in proximal tubular
cells in a number of experimental models of protein-
uric nephropathies [23]. Intracellular C3 staining was
present in proximal tubular cells prior to the develop-
ment of inflammation [29]. Activation of complement
system in tubular cells is associated with alterations of
the cytoskeleton, production of reactive oxygen species,
and synthesis of proinflammatory mediators [30].
Podocyte dysfunction
Recent data are in support of the possibility that the
excessive protein load of the cells can be a factor under-
lying progressive podocyte injury (Fig. 1) [31]. Signs of
enhanced uptake of plasma proteins by podocytes, as as-
sessed by immunofluorescence analysis of albumin, IgG
and complement C3, were found in remnant kidneys of
rats with 5/6 renal mass reduction at 7 days after surgery,
in a very early stage of disease. The granular intracellu-
lar pattern was entirely consistent with accumulation of
proteins by endocytosis. By dual staining of sections of
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Fig. 1. Schematic representation of podocyte
disfunction caused by protein overload in
chronic nephropathies. Abbreviations are:
ACEi, angiotensin-converting enzyme in-
hibitor; ARB, angiotensin II receptor block-
ers; TGF-b , transforming growth factor-b .
kidneys taken at 14 days after surgery, the abnormal ex-
pression of desmin, a marker of podocyte injury, was
confined to the podocytes showing intracellular staining
for plasma proteins. In addition, protein-laden podocytes
showed loss of expression of synaptopodin, an actin-
associated molecule first detectable during foot process
formation and thus an indicator of differentiated pheno-
type of the cell. These data were taken to suggest that
the enhanced endocytosis of protein may concur to the
perturbation of podocyte function that is currently rec-
ognized to play major role in generating adhesive le-
sion and sclerosis. A causal link between protein load
and podocyte dysfunction indeed was established by find-
ings that the exposure of cultured podocytes to albumin
(10 mg/mL) induced both loss of synaptopodin staining
and expression and release of TGF-b1, a major stimu-
lus for extracellular matrix production in the glomeru-
lus. Moreover, the conditioned medium of albumin-laden
podocytes induced the expression of the myofibroblast-
associated molecule a-smooth muscle actin in cultured
mesangial cells. Such response was inhibited by the addi-
tion of neutralizing anti-TGF-b1 antibody.
To dissect the relative contribution of angiotensin II
and proteinuria on chronic renal damage, we used a pro-
tein overload model of nephropathy in animals with tar-
geted gene deletion of the angiotensin II type 1A receptor
(AT1 −/−) as compared to wild-type mice (AT1 +/+). A
group of normal animals not exposed to overload pro-
teinuria acted as control.
AT1 −/− animals developed proteinuria, renal failure,
and glomerular sclerosis, although to a lesser degree than
AT1 +/+ animals. In both models renal endothelin-1 ex-
pression and synthesis was increased as compared to nor-
mal contros. These data confirm that protein trafficking
through the glomerular barrier has an intrinsic toxicity
that is independent from the mediation of angiotensin II
[32].
The activation of a variety of molecules, such as cy-
tokines, growth factors, and vasoactive substances, may
result in abnormal accumulation of extracellular matrix
collagen, fibronectin, and other components that are re-
sponsible for interstitial fibrosis. The proinflammatory
mediators promote local recruitment of macrophages and
lymphoctes [33], which, in turn, can stimulate the trans-
formation of interstitial cells into myofibroblasts. Prox-
imal tubular epithelial cells can interact with interstitial
fibroblasts to promote fibrogenesis via release of profi-
brogenic molecules [34].
In summary, there is robust experimental evidence and
a number of hints from clinical observations that protein-
uria is responsible for interstitial inflammation and subse-
quent fibrosis, thereby contributing to progressive renal
function loss.
THE CONCEPT OF RENOPROTECTION
The experimental demonstration that the blockade of
angiotensin II with an angiotensin-converting enzyme
(ACE) inhibitor slowed the progressive loss of renal func-
tion in a number of animal models or renal diseases,
including diabetic nephropathy [35, 36], offered the op-
portunity, for the first time, to devise a treatment strategy
that was not limited to passively accompany patients to
their destiny of dialysis, but was aimed to preserve renal
function as long as possible. The concept of renoprotec-
tion has then emerged.
In rats with renal mass reduction or diabetic nephropa-
thy, ACE inhibitors reduced glomerular capillary
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hypertension and slowed renal disease progression, while
other antihypertensive drugs did not reduce glomerular
hypertension and did not prevent progression, even if sys-
temic blood pressure was controlled [35]. In these early
experiments, ACE inhibitors have shown that these com-
pounds reduced proteinuria in animals.
The antiproteinuric effect has been initially attributed
to the reduction of glomerular hypertension, but a direct
effect of ACE inhibitors on glomerular membrane per-
meselectivity to macromolecules has been also demon-
strated [37].
In in vitro and in vivo experiments, ACE inhibitors are
able to prevent the expression of inflammatory media-
tors such as NF-kB, RANTES, MCP-1, and insulin-like
growth factor [38]. This may result both from inhibition of
angiotensin II, whose proinflammatory properties have
been described, and from decreased exposure of tubular
cells to toxic effect of proteins.
In the remnant kidney model, the ACE-inhibitor treat-
ment limited the up-regulation of TGF-b1 in podocytes,
as well as the abnormal expression of a-smooth muscle
actin in mesangial cells [38].
The development of a new class of the drugs, the
angiotensin receptor blockers (ARBs) has offered an-
other opportunity to further improve the renoprotec-
tion. The combination of two drugs, an ACE inhibitor
and an ARB, in an experimental model of chronic
nephropathies was associated with greater reduction of
proteinuria and a trend toward less renal injury than with
each drug alone [39]. The near complete abolition of an-
giotensin II activity is instrumental to achieve full renal
protection.
Until now, we have considered as the main goal of our
treatments the arrest of renal disease progression. How-
ever, the kidney has a great potential of regeneration after
injury. Experimental evidence is accumulating that there
is potential for regression of renal scarring, as shown in
a recent paper by Fogo [40], in which the mechanisms of
regeneration are reviewed. Of note, the potential antifi-
brotic role of drugs that block the renin-angiotensin II
system is underlined [41].
TRANSLATION OF EXPERIMENTAL RESULTS
IN CLINICAL TRIALS
The 1980s have been the decade of the experimental
studies and the 1990s the decade of the translation of the
experimental evidence into clinical trials. A number of
small studies were performed to assess the protective ef-
fects of ACE inhibitors in chronic nephropathies, but the
first statistically robust demonstration of the validity of
such approach was provided by an American collabora-
tive study in type 1 diabetes who had proteinuria greater
than 500 mg/day and serum creatinine concentration was
< or = 2.5 mg/dL [42].
Two hundred seven patients received captopril and 202
received a placebo. The primary end point of doubling
the base-line serum creatinine concentration was reached
in 25 patients in the captopril group, as compared with
43 patients in the placebo group (P = 0.007). Captopril
treatment was associated with a 50% reduction in the risk
of the combined end points of death, dialysis, and trans-
plantation that was independent of the small disparity in
blood pressure between the groups.
The role of proteinuria as a promoter of progression
and its impact on renal outcome was explored by the
Ramipril Efficacy in Nephropathy (REIN) study [43].
This study was designed to assess the hypothesis that
ACE inhibition could be superior to other antihyperten-
sive drugs in reducing proteinuria, limiting the decline in
GFR, and preventing end-stage renal disease in patients
with chronic nephropathies. In this study, patients were
randomly assigned to receive ramipril or conventional
antihypertensive therapy to maintain diastolic blood
pressure at 90 mm Hg or less. A prestratification strat-
egy recognized two levels of proteinuria (stratum 1 >1
and <3 g/24 hours; stratum 2 ≥ 3 g/24 hours).
The study showed that while blood pressure control
was similar in the two treatment groups, ACE inhibitor
therapy decreased the progression to end-stage renal dis-
ease by 50% [43, 44]. Among patients with proteinuria of
3 g/24 hours or more, those who received the ACE in-
hibitor had a significantly slower rate of decline in GFR
than did patients receiving conventional antihypertensive
therapy. It was also found that the ramipril-induced re-
duction in rate of urinary protein excretion was the only
time-dependent covariate that predicted a lower decline
in GFR and lower incidence of progression to end-stage
renal disease; this finding clearly indicated that renopro-
tection is linked to reduction of protein traffic.
The study was continued for 2 years (the REIN follow-
up study), during which period all patients previously on
placebo were switched to ACE inhibitor [44]. In patients
continuing to receive ramipril, GFR further decreased
to approximately 1 mL/min per year during follow-up, a
figure similar to that associated with normal aging.
Patients who switched from conventional therapy to
ramipril also benefited from the treatment.
One of the most impressive findings of this prolonged
follow-up, was that after about 36 months of treatment
with ramipril, no additional patients progressed to the
point of requiring dialysis, whereas patients switched
from conventional therapy to ramipril continued to de-
velop end-stage renal disease. To further investigate
the nature of the time-dependent improvement in GFR
change, it was looked for a break point in the individ-
ual GFR slopes of patients receiving continued ramipril
therapy. It could be predicted that after the break
point, ten patients receiving continued ramipril therapy
would never progress to end-stage renal disease and that
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another ten had such improved GFR slopes that progres-
sion to end-stage renal disease would be delayed by about
5 years.
This analysis provides evidence that the tendency of
GFR to decline with time can be halted and remission is
achievable in some patients with chronic renal disease.
The decade of large clinical trials in nephrology was
closed when the results of three important studies were
published in the New England Journal of Medicine
[45–47]. All three studies examined the role of ARBs in
type 2 diabetic nephropathy. The role of ARBs in overt
diabetic nephropathy was explored in two trials published
in 2001. In one study, 1715 patients with type 2 diabetic
nephropathy were randomized to receive ARB irbesar-
tan [45], calcium channel blocker amlodipine, or placebo.
The primary composite end point was doubling of serum
creatinine, end-stage renal disease, or death. Treatment
with irbesartan resulted in a risk reduction for primary
composite end point of 20% lower than placebo and 23%
than amlodipine.
The Reduction of End Points in NIDDM with the
Angiotensin II Antagonist Losartan (RENAAL) study
evaluated the renal protective effect of losartan versus
placebo (on top of conventional antihypertensive ther-
apy, with the exclusion of ACE inhibitors) in 1513 patients
with overt type 2 diabetic nephropathy [46]. The primary
composite end point was doubling of serum creatinine,
end-stage renal disease, or death. The ARB losartan re-
duced the incidence of doubling serum creatinine by 25%
and the risk of end-stage renal disease by 28%. The death
rate was similar in the two groups, which both attained
the same blood pressure level. Proteinuria declined by
35% in losartan group.
A statistical review and evaluation by the Food and
Drug Administration, available to the public on the in-
ternet [47], showed that there may be a difference in the
effect of losartan in terms of hazard reduction between
Asia and other regions of the world. Patients recruited in
Asia appeared to benefit from losartan to a greater ex-
tent than patients from other regions. As a matter of fact,
most of the benefit of losartan in this study seems to be
due to the results in Asian patients.
One other study evaluated the renoprotective effect of
the ARB irbesartan in hypertensive patients with incip-
ient nephropathy [48]. The end point of the study was
the time of onset of overt albuminuria. In 2 years follow-
up, only 5.2% of patients receiving 300 mg of irbesartan
reached the end point, as compared with 14.9% of pa-
tients on placebo. The groups had similar blood pressure
control, a finding that suggests that ARBs are renopro-
tective independently of their antihypertensive effect.
Although we have limited our review to only a few
clinical studies, several other trials have been published,
some of them small in size, with little statistical power,
and with short follow up. However, they all point in one
direction: blockade of renin-angiotensin system is ben-
eficial in most chronic nephropathies. There is also the
support of meta-analysis, which concluded that ACE in-
hibition is superior to other antihypertensive treatment in
preventing progression of nondiabetic renal disease [49].
This may be not true in overt nephropathy of type 2
diabetes. The results of several clinical trials have shown,
with one exception, that no significant difference was
found in terms of renoprotection, as measured as preven-
tion of GFR decline over time, between ACE inhibitors
and other antihypertensive agents [50]. Indeed, in pa-
tients with type 2 diabetic nephropathy, overt protein-
uria, and renal insufficiency, an ACE inhibitor was not
able to modify renal hemodynamics and glomerular siev-
ing properties, despite effective blood pressure control
[51]. In summary, currently available treatments have uni-
formly shown that reduction of blood pressure per se is
beneficial in patients with type 2 diabetic nephropathy,
while the effect of renin-angiotensin system blockade is
probably less relevant than in type 1 diabetic nephropa-
thy or nondiabetic nephropathies. However, as Thomas
Starzl once said in another context, “Whenever that hap-
pens, if door opens a little bit, then there is a crush of
effort to try to jam it open.” The results of the last decade
of experiments and trials are an important platform of
knowledge to devise the best strategy in preventing dia-
betic nephropathy in the next 10 years.
THE FUTURE OF RENOPROTECTION
The evidences from both experimental studies and clin-
ical trials suggest that the current practice can at the best
postpone end-stage renal disease for few years, and not
avoid dialysis for most patients during their lifetime. The
dream of no more dialysis is still largely a dream, but
nephrologists are doing their best to reduce the number
of patients reaching end-stage renal disease. It is some-
what paradoxical that renal doctors, probably the only
ones among their peers, are working hardly to reduce
their own business.
Not all goals are likely to be met in the short term. We
have already described the apparent resistance to current
therapies of type 2 diabetic nephropathy.
Two other important cause of uremia are polycystic
kidney disease and chronic allograft rejection. Polycystic
kidney disease is object of intensive investigation con-
cerning the molecular genetic and cellular pathophysio-
logic mechanisms responsible for the development of the
disease, and a great many potential therapeutic agents
or treatment strategies are under scrutiny [52]. The next
two decades will probably witness the development of the
clinical phase of these studies.
Allograft rejection is becoming the third cause of
end-stage renal disease in several countries. Studies
aimed to improve current antirejection therapy, or induce
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Fig. 2. Algorithm of the remission clinic for
chronic nephropathies. In the box the tar-
gets for remission clinic are reported. Abbre-
viations are: ACEi, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II recep-
tor blockers. CCB, calcium channel blockers;
LDL, low-density lipoprotein; VLDL, very
low-density lipoprotein; HbA1c, hemoglobin
A1c.
longlasting tollerance, are under way and hold promise
for the future [53].
A significant reduction of the incidence of end-stage
renal disease is likely to be achieved in the next future
for nondiabetic chronic nephropathies, provided that we
can improve the degree of renoprotection. This goal may
be attainable with a more complex strategy than with a
single pharmacologic intervention.
In analogy with other major medical diseases, for ex-
ample cancer, HIV infection, organ transplantation, a
multidrug intervention may be the strategy needed to sig-
nificantly retard dialysis [54]. Experimental and clinical
data support this notion. In an animal model of nephrotic
syndrome, the accelerated passive Heyman nephritis, the
addition of an ARB to an ACE inhibitor lessened the
damage, and the further addition of lipid-lowering drug
further amelioreted the outcome [39]. On the clinical
ground, there are few trials that show that the com-
bination of an ACE inhibitor with an ARB afford a
greater renoprotection than each drug used alone. The
COOPERATE study [55] compared a combined treat-
ment of ACE inhibitor and angiotensin II receptor
blocker, with monotherapy of each drug at its maximum
dose, in patients with nondiabetic renal disease. Eleven
percent of patients on combination treatment reached the
combined primary end point of time to doubling of serum
creatinine concentration or end-stage renal disease com-
pared with 23% of patients on trandolapril alone (haz-
ard ratio 0.38, 95% CI 0.18–0.63, P = 0.018) and 23% of
those on losartan alone (hazard ratio 0.40, 95% CI 0.17–
0.69, P = 0.016). Although good, these results show that
further strategies for complete management of progres-
sive nondiabetic renal disease is still elusive, since some
patients reached the primary end point on combined
treatment.
Interest has been growing lately on the potential role of
an aldosterone blocking agent, eplerenone, in cardiovas-
cular diseases [56]. Data presented at the 62nd Scientific
Session of the American Diabetes Association suggested
that the association of eplerenone and enalapril reduced
microalbuminuria in type 2 diabetic patients to a greater
extent than each drug alone, although hyperkalemia was
a cause of withdrawal from the study for a significant
number of patients [57].
Looking for a more effective treatment, the role of
lifestyle changes should not be overlooked. Smoking ces-
sation per se may reduce disease progression by 30%,
which qualifies as the single most important renopro-
tective measure [58]. Physical activity has always been
considered instrumental to the loss of excess weight,
but it may have an intrinsic favorable effect, as docu-
mented by a small study in 20 patients with chronic kid-
ney disease who were assigned to 12-week regular aquatic
exercise or the armchair [59]. During this short period of
time, the body mass index did not change in either group.
However, proteinuria decresed by 50% in those who per-
formed aquatic exercise, while it did not change in the
sedentary group.
The multidrug approach to chronic nephropathies has
been formalized in an interventional protocol that has
been named remission clinic (Fig. 2) [60]. Patients with
chronic kidney disease and proteinuria greater than
1 g/24 hours are initially treated with a low starting dose of
an ACE inhibitor, which is then increased up to the max-
imum dose. Then, if the goals of blood pressure <120/80
mm Hg and proteinuria <0.3 g/24 hours are not achieved,
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an ARB is added at half-maximum dose. Again, dose is
increased stepwise. Throughout this uptitration of ACE
inhibitor, or ARB, for optimal blood pressure control or
prevention of hypokalemia, the addition of diuretics is
usually needed. If, after this step target blood pressure
and proteinuria are not achieved, the next antiprotein-
uric drug to be added is usually a nondihydropiridinic
calcium channel blocker.
In those with serum low-density lipoprotein (LDL)
cholesterol >100 mg/dL, a statin is added, and in those
with diabetes glycemic control is reinforced to achieve
hemoglobin A1c (HbA1c) <7.5%. Both interventions
(lipid reduction and tight glycemic control) are supposed
to contribute to renoprotection [50, 61].
This multiple drug approach has been tested in more
than 40 patients in our unit, and we could prove that is
feasible and effective. However, it is difficult to test in a
formal study since any further addition of new or old drug
to ACE inhibitors or ARBs in a multiple intervention trial
would require a very large number of subjects and would
be too costly for any company to support [54]. We proba-
bly should make better use of small but well-designed and
rigorously condcted study with carefully selected marker
of renal progression.
The concept of multidrug approach for renal disease is
extraordinarily remiscent of the recent proposal of Law
et al [62] in the British Medical Journal to develop a sin-
gle pill containing aspirin, a statin, three antihypertensive
agents at half dose, and folic acid for the prevention of
cardiovascular disease. The “super” pill, as the media had
immediately dubbed the provocative proposal, could be
indeed valuable, perhaps with some adjustments, for pa-
tients with chronic nephropathies.
One of the potential advantages of this “super” pill
is that such intervention could be made available also to
patients of poor countries. There are little and sparse data
on incidence and prevalence of chronic kidney diseases
in developing countries [63]. What is certain is that in all
low-income countries there are no dialysis facilities, or
not enough for all in need, and people still die of uremia.
Simple and unexpensive screening programs are fea-
sible at low cost in poor countries, and also simple and
unexpensive treatments are plausible and possibly effec-
tive. As an example, the Kidney Help Trust Rural Project
in India [64] was able to screen for high blood pressure,
diabetes, and chronic kidney disease in a rural popula-
tion of 25,000 people with the help of six health social
workers, at a cost of less than $ 6000 per year, a mere
25 cents per capita. An excellent blood pressure control
was achieved among hypertensive patients, while blood
glucose control in diabetics was considered good. This
could be the perfect condition to test the validity of the
idea of a “super” pill.
The cost is the key factor to be considered here. A
number of strategies have been devised to increase the
access to essential medicine where they are most needed,
from discounted prices for medicine, softening of patent
protection, drug donation [65]. Among several possi-
ble funding stategies, a global fund for kidney disease,
modeled on the example of the Global Fund for AIDS,
Tuberculosis and Malaria, may be proposed. Drug com-
panies, whose products such as ACE inhibitors and other
antihypertensive drugs have proved to be very prof-
itable, and also of dialysis machine manufacturers, whose
earnings are colossal, could support such a fund with a
minimal percentage, 1% to 3%, of the revenues from an-
tihypertensive drugs or dialysis product. The contribution
by the industry to the fund for the advancement of the
global health, even with small part of the profit, is a moral
obligation.
Of course the government, the intergovernamental in-
stitutions like the World Health Organization (WHO),
the World Bank, and UNO, and nongovernamental orga-
nizations are called to play their role and it is a fundamen-
tal one. Also the International Society of Nephrology,
by establishing the Commission for the Global Advance-
ment of Nephrology (COMGAN), whose chairmen were
Barry Brenner and John Dirks from 1993 to 1999, and
who have committed themselves to the cause of combat-
ing kidney disease worldwide, especially in developing
countries.
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